Sebastian Biopharma is a preclinical oncology company developing tumor-targeted, multi-pathway therapeutics to address immunotherapy-resistant cancers where most patients with solid tumors fail to achieve durable benefit. SBP-001 is an industry-compliant dual-payload antibody–oligonucleotide conjugate (dpAOC) designed for tumor specific delivery and simultaneous modulation of two key intracellular pathways, targeting major drivers of tumor resistance while minimizing systemic toxicity. The company has completed target discovery, validation, and feasibility, demonstrating human-relevant biology, in-vitro potency, and supportive in-vivo efficacy and tolerability. Discovery Optimization is the next value inflection point, focused on selecting 2–4 pre-candidates. Founder capital has been deployed, providing operational runway through August 2026. The company is raising a Pre-Seed round in two milestone-driven tranches to achieve SBP-001 candidate nomination over 12-18 months.